Testing a new device for metastatic triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new device called TheraBionic P1 for patients with metastatic triple-negative breast cancer who have already tried at least two other treatments without success. The device is non-invasive and may help slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 22 or older
- You have triple-negative breast cancer that has spread to other parts of the body (metastatic)
- You have already tried at least two different standard treatments for your metastatic breast cancer, and they stopped working or caused side effects
- You have not had chemotherapy or other cancer therapy in the last 14 days
- You have a life expectancy of at least three months and are well enough to be out of bed for more than half the day
- You do not have untreated brain metastases, active mouth sores, or a severe nickel allergy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a research tool that may help doctors choose the best treatment for people with advanced triple-negative breast cancer. You will have a biopsy and blood draw to help see how the tool works.
This trial tests whether using blood tests and MRI imaging to monitor how your tumor responds can help doctors personalize your chemotherapy and immunotherapy treatment before surgery. The goal is to improve outcomes for people with early-stage triple-negative breast cancer.
This Phase 2 trial tests a treatment for people with triple-negative breast cancer that has come back or spread and has continued to progress despite earlier therapies. It may help by trying a new approach in patients who still have enough health to safely receive more treatment.
This Phase 2 trial tests a treatment plan for triple-negative breast cancer that has come back or kept progressing after prior immunotherapy (sometimes along with targeted therapy or chemotherapy). It may help by trying to make the cancer more controllable when it has become resistant to earlier treatment.
This trial tests a new combination of drugs for triple negative breast cancer that has worsened after prior immunotherapy. The goal is to see if these treatments can shrink tumors and help patients who have not responded to earlier immunotherapies.
This trial tests a device called TheraBionic P1, which uses low-level radiofrequency energy to treat advanced breast cancer that has stopped responding to standard treatments. It may offer a new option for people who have exhausted other therapies.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.